HPV-6 antigens × HPV-11 antigens

PRECIGEN, INC.
PRECIGEN, INC. (PGEN)
WebsitePrice
Market cap
Next catalystExpected 2026PAPZIMEOS — planned pediatric RRP study · Trial initiationSEC filing ↗
Cash
Chart & Events
Core Clinical
PAPZIMEOS (zopapogene imadenovec-drba; PRGN-2012)PAPZIMEOS — planned pediatric RRP study
PreINDP1P2FilingApproved
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Clinical
Upcoming clinical milestones
PAPZIMEOS (zopapogene imadenovec-drba; PRGN-2012)PAPZIMEOS — planned pediatric RRP study
HPV-6 antigens × HPV-11 antigens
PreINDP1P2FilingApproved
Other pipelines
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Approved / commercial
Approved
PreINDP1P2P3FilingApproved